CURRICULUM VITAE

Chow L.W.C.
CURRI CULUM VIT A E
PERSONAL PARTICULARS
NAME:
SEX:
Louis Wing-Cheong CHOW
Male
QUALIFICATIONS
Basic Qualification:
Postgraduate Qualifications:
M.B.B.S. (HK)
F.R.C.S. (Glasgow)
F.C.S. (HK)
F.H.K.A.M.(Surgery)
M.S. (HKU)
F.A.C.S.
May 1984
May 1988
December 1990
December 1993
December 1999
October 2004
SABBATICAL TRAINING
Breast Service
Jul – Nov 1994
Department of Surgery, Memorial Sloan Kettering Cancer Center,
New York, USA
Division of Surgical Oncology
Jan 1993
Department of Surgery, University of Southern California, Los
Angeles, USA
Division of Surgical Oncology
Oct – Dec 1992
Department of Surgery, Yale University, USA
Gastric & Mixed Tumors Service
Jul – Sep 1992
Department of Surgery, Memorial Sloan Kettering Cancer Center,
New York, USA
PRESENT APPOINTMENTS
Visiting Professor
Oct 2008 – present
Wuhan University of Science and Technology
P.R. China
Honorary Consultant
Feb 2008 – present
Kiang Wu Hospital, Macau SAR
Honorary Professor
Dec 2007 - present
Ningxia Medical College School of Clinical Medicine ,
Ningxia, P.R. China
Medical Director
Jan 2006 – present
Comprehensive Centre for Breast Diseases
UNIMED Medical Institute, Hong Kong SAR
Honorary Professor
Apr 2004 – present
Tohoku University, Sendai, Japan
1
Chow L.W.C.
PRESENT APPOINTMENTS IN PROFESSIONAL ASSOCIATIONS
Editorial Board Member
Sep 2011 – present
Breast Case
Editorial Board Member
Aug 2010 – present
Chinese Journal of Clinicians (CJC)
Executive Board Member
Jun 2010 – present
European-Asian Society for Breast Disease (EURAMA)
Editorial Board Member
May 2010 – present
Journal of Angiogenesis Research
Editorial Board Member
Jan 2010 – present
Chinese Journal of Cancer Research
Executive Committee Member
Oct 2009 – present
Chinese Society of Clinical Oncology
Deputy Editor-in-Chief
Oct 2008 – present
Editorial Board, Chinese Journal of Breast Disease (Electronic
Edition)
Vice-Chairman
Oct 2008 – present
Breast Group, Oncology Branch, Chinese Medical Association
Executive Chief Editor
Jul 2007 – present
Editorial Board, Chinese Journal of Traditional and Western
Medicine
Executive Director
Dec 2002 – present
Organisation for Oncology and Translational Research
Executive Member
Apr 1999 – present
Asian Breast Cancer Society
PREVIOUS APPOINTMENTS
Honorary Secretary
Dec 2008 – 2012
The Hong Kong Academy of Medicine, Hong Kong SAR
Honorary Clinical Professor
Nov 2008 – 2012
Clinical Trials Centre, Li Ka Shing Faculty of Medicine
The University of Hong Kong, Hong Kong SAR
Member
Jul 2007 – 2012
Steering Committee on e-Health Record Sharing
Food and Health Bureau, Government Secretariat,
Hong Kong SAR
Member
Mar 2002 – 2004
Task Group on Breast Cancer Management
Hospital Authority, Hong Kong SAR
Member
Jul 2001 – Dec 2001
Task Group on Re-development of Li Shu Fan Building
The University of Hong Kong, Hong Kong SAR
2
Chow L.W.C.
Honorary Secretary
Feb 2001 – Dec 2004
Hong Kong Association for Integration of Chinese -Western
Medicine
Director
Jan 2001 – Dec 2005
Hung Chao Hong Integrated Centre for Breast Diseases
Tung Wah Hospital, Hong Kong SAR
Editor
Jun 2000 – Dec 2005
Medical Faculty News, Faculty of Medicine
The University of Hong Kong, Hong Kong SAR
Associate Dean (Community Relations)
Jan 2000 – Mar 2001
Faculty of Medicine
The University of Hong Kong, Hong Kong SAR
Member
Sep 1999 – Dec 2005
Board of Studies, School of Chinese Medicine
The University of Hong Kong, Hong Kong SAR
Deputy Director
Jun 1999 – Dec 2005
Centre of Education and Training, Department of Surgery
The University of Hong Kong, Hong Kong SAR
Board Member
Jan 1999 – Jun 1999
Steering Committee, Clinical Trial Centre
The University of Hong Kong, Hong Kong SAR
Fellow, Centre of Endocrinology and Diabetes
Sep 1998 – Dec 2005
The University of Hong Kong, Hong Kong SAR
Fellow, Cancer Research Centre
Sep 1998 – Dec 2005
The University of Hong Kong, Hong Kong SAR
Chairman
Jun 1998 – Dec 2005
Clinical Skills Planning Group
New Medical Curriculum
Associate Professor
Mar 1997 – Dec 2005
Department of Surgery
The University of Hong Kong, Hong Kong SAR
Honorary Consultant
Jul 1996 – Dec 2005
Department of Surgery, Tung Wah Hospital, Hong Kong SAR
Honorary Consultant
Jul 1996 – Dec 2005
Department of Surgery, Queen Mary Hospital, Hong Kong SAR
Chief, Division of Breast Surgery
Jul 1995 – Dec 2005
The University of Hong Kong, Hong Kong SAR
Assistant Professor
Apr 1993 – Mar 1997
Department of Surgery,
The University of Hong Kong, Hong Kong SAR
3
Chow L.W.C.
PREVIOUS APPOINTMENTS IN PROFESSIONAL ASSOCIATIONS
President (Asia-Africa)
2008 – 2009
Senologic International Society (SIS)
Vice-President
Jun 2000 – 2011
Hong Kong Day Surgery Association
President
Oct 1999 – Sep 2000
Asian Breast Cancer Society
Honorary Secretary
Jul 1995 – Jun 1997
Hong Kong Day Surgery Association
Honorary Secretary
Jul 1995 – Jun 1997
University Medical Doctors’ Association
Council Member
Jul 1995 – Jun 1997
Public Doctor Association, Hong Kong SAR
PROFESSIONAL MEMBERSHIP
Hong Kong:
Hong Kong Medical Association
International:
International Society of Surgery
American Association of Cancer Research
Asian Surgical Association
American Society of Breast Disease
Breast Surgery International
American Society of Breast Surgeons
TEACHING DUTIES AND EXPERIENCE
Courses Attended
Breast Sonography Program
Jun 2004
Institute of Ultrasound, St Peterburg, Florida, USA
Radioguided Surgery and Minimally Invasive Breast Biopsy
Jun 2001
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
Program for Advanced Medical Education
Dec 1999
Harvard Medical School, Boston, USA
Courses Taught
Radioguided Surgery Course, Chengdu
Nov 2003
Department of Surgery
Xua Shi Medical School, P.R. China
Breast Cancer
Understanding Cancer
Broadening Courses in Culture and Value Studies and Theme Studies
The University of Hong Kong
4
1999 –
present
Chow L.W.C.
Principles of Surgical Treatment of Cancer
Understanding Cancer
Broadening Courses in Culture and Value Studies and Theme Studies
The University of Hong Kong
Management of Advanced Stage Breast Cancer
1999 –
present
Dec 1998
Diploma in Oncology & Palliative Care for Health Care Professionals
School of Professional & Continuing Education, The University of Hong
Kong
Breast Cancer – Screening & Surgical Treatment
Jul 1997
Diploma in Oncology & Palliative Care for Health Care Professionals
School of Professional & Continuing Education, The University of Hong
Kong
Mock Viva on Breast Diseases
Jul 1997
Advanced Course in Surgery
Department of Surgery, The University of Hong Kong
Management of Breast Cancer
Jul 1997
Advanced Course in Surgery
Department of Surgery, The University of Hong Kong
Breast Cancer
Apr 1997
Certificate Course in Clinical Oncology
Department of Nursing Studies, The University of Hong Kong
Surgery and Breast Cancer
Aug 1996
Advanced Course in Breast Cancer Nursing, Hong Kong SAR
Classification and Staging of Breast Cancer
Aug 1996
Advanced Course in Breast Cancer Nursing, Hong Kong SAR
Seminars and Interactive Teaching
Tutor, Health Care Project for Phase I Students
Faculty of Medicine, The University of Hong Kong,
2001 –
present
Lecturer, whole class session on “Breast Mass”
Phase I
Department of Surgery, The University of Hong Kong,
Chief Co-ordinator of Teaching in Network Hospitals
Phase II, Block B, Department of Surgery, The University of Hong Kong,
Chief Co-ordinator of Teaching Clinic
Phase I, Block B, Department of Surgery, The University of Hong Kong,
PBL Tutor
Phase I, Block B
Department of Surgery, The University of Hong Kong,
PBL – Case Writer of Breast Cancer
1998 –
present
1998 –
present
1997 –
present
Phase I, Block B, Department of Surgery, The University of Hong Kong,
1997 –
present
Interactive Teaching on Breast Diseases
1996 – 1999
Junior Clinical Clerkship
Department of Surgery, The University of Hong Kong,
5
Chow L.W.C.
Clinical Demonstration on Breast Examination
Introductory Clinical Course
Department of Surgery, The University of Hong Kong,
Seminars and Tutorials
1995 –
present
1995 – 1999
Special Clinical Clerkship
Department of Surgery, The University of Hong Kong,
Course Director
Minimally Invasive Breast Biopsy Course
Nov 2004
Department of Surgery, The University of Hong Kong,
Radioguided Surgery Course for Breast Cancer
Jun 2004
Department of Surgery, The University of Hong Kong,
Radioguided Surgery Course for Breast Cancer
Nov 2003
Department of Surgery, The University of Hong Kong,
Radioguided Surgery Course for Breast Cancer
Nov 2002
Department of Surgery, The University of Hong Kong,
Radioguided Surgery Course for Breast Cancer
Mar 2002
Department of Surgery, The University of Hong Kong,
Summer Broadening Course
2001
Faculty of Medicine, The University of Hong Kong,
Summer Broadening Course
2000
Faculty of Medicine, The University of Hong Kong,
RESEARCH ACTIVITIES
Thesis
Master of Surgery
Modification of acute inflammatory response phase response
caused by surgical trauma in a mastectomy model
Degree conferred in December 1999
Journal Articles Published
1.
Case report: postradiation chondrosarcoma with a short latency period of 6
months
Yang S, Tang W, Tang XF, Xuan M, Guo LJ, Wang XY, Loo WT, Liu Q, Chow LW,
Cheung MN, Tsang W
Int J Biol Markers 2014 Nov 8:0
2.
Outcomes of adjuvant endocrine therapy and hormone receptor status change
following neoadjuvant chemotherapy in breast cancer patients
Wu JY, Chen WG, Chen XS, Huang O, He JR, Zhu L, Li Y, Shen KW, Chow LW, Loo
WT, Chow CY, Tsang W
Int J Biol Markers 2014 Nov 5:0
3.
Suppression of C6 gliomas via application of rat hyperplasia gene.
Gao P, Wang Z, Zhang B, Zou Y, Guo H, Liu H, Yang Q, Fang Z, Jiang S, Shen B,
Chow LW, Loo WT, Ng EL, Tsang WW.
Int J Biol Markers. 2014 Oct 8:0. doi: 10.5301/jbm.5000114.
6
Chow L.W.C.
4.
5.
Epigenetic changes of TIMP-3, GSTP-1 and 14-3-3 sigma genes as indication of
status of chronic inflammation and cancer.
Wang YJ, He L, Yuan M, Tsang WW, Hao L, Wang M, Chow LW, Cheung MN, Liu
Q, Ng EL, Loo WT, Chow CY, Bai LJ, Yang Z.
Int J Biol Markers. 2014 Sep 30;29(3):e208-14. doi: 10.5301/jbm.5000104.
Correlation of tumor-infiltrative lymphocyte subtypes alteration with
neoangiogenesis before and after neoadjuvant chemotherapy treatment in
breast cancer patients
Chan MS, Chen SF, Felizola SJ, Wang L, Nemoto N, Tamaki K, Ishida T, Chow LW,
Ohuchi N, Sasano H
Int J Biol Markers 2014 Sep 30;29(3):e193-203
6.
Challenges to effective cancer control in China, India, and Russia
Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y,
Liedke PE, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao
Z, Wu YL, Fan D, Chow LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A,
Sullivan R, Badwe R, Banavali SD, Nair R, Kumar L, Parikh P, Subramanian S,
Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-Perez-de-Celis E, Adilbay D,
Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S, Danishevskiy KD,
Hurlbert M, Vail C, St Louis J, Chan A
Lancet Oncol 2014 Apr;15(5):489-538
7.
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial
in postmenopausal women evaluating first-line endocrine therapy in locally
advanced or metastatic hormone receptor-positive/HER2-negative breast
cancer
Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P,
Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Oncologist 2014 Apr;19(4):348-9
8.
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II
trial in postmenopausal women with previously treated locally advanced or
metastatic hormone receptor-positive/HER2-negative breast cancer
Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P,
Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Oncologist 2014 Apr;19(4):346-7
9.
Angiotensin II induces mitochondrial dysfunction and promotes apoptosis via
JNK signalling pathway in primary mouse calvaria osteoblast.
Li G, Wang M, Hao L, Loo WT, Jin L, Cheung MN, Chow LW, Ng EL.
Arch Oral Biol. 2014 May;59(5):513-23. doi: 10.1016/j.archoralbio.2014.02.015.
Epub 2014 Mar 4.
10.
A pilot study: application of hemoglobin and cortisol levels, and a memory test
to evaluate the quality of life of breast cancer patients on chemotherapy.
Loo WT, Yip MC, Chow LW, Liu Q, Ng EL, Wang M, Chen J.
Int J Biol Markers. 2013 Dec 17;28(4):e348-56. doi: 10.5301/jbm.5000053.
11.
Randomized trial of preoperative docetaxel with or without capecitabine after 4
cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage
breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for
response to neoadjuvant chemotherapy
Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H,
Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba
M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E,
Yoshida N, Toi M
Breast Cancer Res Treat 2013 Nov;142(1):69-80
7
Chow L.W.C.
12.
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2positive metastatic breast cancer
Chow LW, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, Vo Van ML, Bondarenko I
Br J Cancer 2013 May 28;108(10):1985-93
13.
Comparative evaluation of cytokines in gingival crevicular fluid and saliva of
patients with aggressive periodontitis
Yue Y, Liu Q, Xu C, Loo WT, Wang M, Wen G, Cheung MN, Bai LJ, Dou YD, Chow
LW, Hao L, Tian Y, Li JL, Yip AY, Ng EL
Int J Biol Markers 2013 Apr 23;28(1):108-12
14.
New developments in breast cancer prognosis: molecular
predictors of
treatment response and survival
Foo EM, Boost MV, Wong AS, Loo WT, Chow LW, Chow CY
Int J Biol Markers 2013 Jun 28;28(2):e131-40
15.
Status of oral ulcerative mucositis and biomarkers to monitor posttraumatic
stress disorder effects in breast cancer patients
Loo WTY, Liu Q, Yip MCW, Wang M, Chow LWC, Cheung MNB, Yip AYS, Ng ELY
Int J Biol Markers 2013 Jun 28;28(2):e168-73
16.
Acceptable cardiac safety profile of neoadjuvant 5 -fluorouracil, epirubicin,
cyclophosphamide and celecoxib (FEC-C) for breast cancer: a subanalysis of
biomarkers for cardiac injury
Chow LWC, Loo WTY, Yip AYS, Ng ELY
Int J Biol Markers 2013 Apr 23;28(1):e92-9
17.
Application of interleukin-1 genes and proteins to monitor the status of chronic
periodontitis
Hao L, Li JL, Yue Y, Tian Y, Wang M, Loo WTY, Cheung MNB, Chow LWC, Liu Q,
Yip AYS, Ng ELY
Int J Biol Markers 2013 Apr 23;28(1):e92-9
18.
Application of biomarkers to sentinel lymph node biopsy for the management of
breast cancer
Liu Q, Loo WTY, Yip AYS, Chow LWC, Ng ELY, Cheung MNB
Chinese Journal of Breast Disease 2013 Mar 21
19.
Association of cytokines, high sensitive C -reactive protein, VEGF and beta defensin-1 gene polymorphisms and their protein expressions with chronic
periodontitis in the Chinese population
Tian Y, Li JL, Hao L, Yue Y, Wang M, Loo WTY, Cheung MNB, Chow LWC, Liu Q,
Yip AYS, Ng ELY, Chow CY
Int J Biol Markers 2013 Apr 23;28(1):e100-e107
20.
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed
by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study
Chow LWC, Tung SY, Ng TY, Im SA, Lee MH, Yip AYS, Toi M, Glück S
Expert Opin Investig Drugs 2013 Mar;22(3):299-307
8
Chow L.W.C.
21.
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral
Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With
Locally Advanced or Metastatic Breast Cancer
Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow LWC, Sun Y,
Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S,
Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF
J Clin Oncol 2012 Dec 10
22.
Changes of tumor infiltrating lymphocyte subtypes before and after
neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer
patients - an immunohistochemical study of cd8+ and foxp3+ using double
immunostaining with correlation to the pathobiological response of the
patients
Chan MSM, Wang L, Felizola SJA, Ueno T, Toi M, Loo WTY, Chow LWC, Suzuki
T, Sasano H
Int J Biol Markers 2012 Dec 27;27(4):e295-304
23.
Evaluation of the psychological and biological changes of patients diagnosed
with benign and malignant breast tumors.
Bai LJ, Liu Q, Wang M, Loo WTY, Cheng RWY, Chow LWC, Cheung MNB, Wei
KYR, Yip AYS, Ng ELY
Int J Biol Markers 2012 Dec 27;27(4):e322-30
24.
Correlation of epigenetic change and identification of risk factors for oral
submucous fibrosis
Xu C, Zhao J, Loo WT, Hao L, Wang M, Cheung MNB, Dou Y, Yip AYS, Ng
ELY, Chow LWC, Liu Q
Int J Biol Markers 2012 Dec 27;27(4):e314-21
25.
The clinical trials of the Organisation for Oncology and Translational Research
(OOTR)
Chow LWC, Toi M
Int J Biol Markers 2012 Dec 27;27(4):e353-6
26.
Prevention of oncological diseases: primary and secondary prevention
Chow LWC, Yip AYS, Ng ELY
Int J Biol Markers 2012 Dec 27;27(4):e337-43
27.
Preoperative systemic therapy in locoregional management of early breast
cancer: highlights from the Kyoto Breast Cancer Consensus Conference
Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson
JF, Sasano H, Cole BF, Chow LWC, Pegram MD, Han W, Huang CS, Ikeda T, Kanao
S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T,
Yamauchi A, Inamoto T
Breast Cancer Res Treat 2012 Dec;136(3):919-26
28.
具抗药性乳腺癌病人的组合性用药治疗方案及其疗效和监察的探讨
Chow LWC, Yip AYS, Liu Q, Loo WTY
The 15th Annual Meeting of Chinese Society of Clinical Oncology (CSCO)
Educational Book, People’s Medical Publishing House, 243-242
29.
Minimally invasive video-assisted thyroidectomy for the early-stage differential
thyroid carcinoma
Yu JJ, Bao SL, Yu SL, Zhang DQ, Loo WTY, Chow LWC, Su L, Cui Z, Chen K, Ma LQ,
Zhang N, Yu H, Yang WZ, Dong Y, Yip AYS, Ng ELY
J of Translational Medicine 2012, 10 Suppl 1: S13
9
Chow L.W.C.
30.
Using association rules mining to explore pattern of Chinese medicinal formulae
(prescription) in treating and preventing breast cancer recurrence and
metastasis
He Y, Zheng X, Sit C, Loo WTY, Wang ZY, Xie T, Jia B, Ye QB, Tsui KC, Chow LWC,
Chen JP
J of Translational Medicine 2012, 10 Suppl 1: S12
31.
Mouse model of plasma cell mastitis
Yu JJ, Bao SL, Yu SL, Zhang DQ, Loo WTY, Chow LWC, Su L, Cui Z, Chen K, Ma L Q,
Zhang N, Yu H, Yang YZ, Dong Y, Yip AYS, Ng ELY
J of Translational Medicine 2012, 10 Suppl 1: S11
32.
Clinical application of human β-defensin and CD14 gene polymorphism in
evaluating the status of chronic inflammation
Loo WTY, Bai LJ, Fan CB, Yue Y, Dou YD, Wang M, Liang H, Cheung MNB, Chow
LWC, Li JL, Tian Y, Qing L
J of Translational Medicine 2012, 10 Suppl 1: S9
33.
Gene polymorphism and protein of human pro - and anti-inflammatory cytokines
in Chinese healthy subjects and chronic periodontitis patients
Loo WTY, Fan CB, Bai LJ, Yue Y, Dou YD, Wang M, Liang H, Cheung MNB, Chow
LWC, Li JL, Tian Y, Qing L
J of Translational Medicine 2012, 10 Suppl 1: S8
34.
Emodin affects ERCC1 expression in breast cancer cells
Fu JM, Zhou J, Shi J, Xie JS, Huang L, Yip AYS, Loo WTY, Chow LWC, Ng ELY
J of Translational Medicine 2012, 10 Suppl 1: S7
35.
Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph
node metastasis
Wei W, Hu H, Tan HS, Chow LWC, Yip AYS, Loo WTY
J of Translational Medicine 2012, 10 Suppl 1: S6
36.
Comparing serum levels of cardiac biomarkers in cancer patients receiving
chemotherapy and subjects with chronic periodontitis
Loo WTY, Yue Y, Fan CB, Bai LJ, Dou YD, Wang M, Liang H, Cheung MNB, Chow
LWC, Li J, Tian Y, Qing L
J of Translational Medicine 2012, 10 Suppl 1: S5
37.
Overexpression of epithelial growth factor receptor (EGFR) predict better
response to neo-adjuvant chemotherapy in patients with triple-negative breast
cancer
Tang YQ, Zhu L, Li YF, Ji J, Li JF, Yuan F, Wang DB, Chen WG, Huang O, Chen XS,
Wu JY, Shen KW, Loo WTY, Chow LWC
J of Tranlsational Medicine 2012 10 Suppl 1: S4
38.
Decreased Expression of C-erbB-2 and CXCR4 in Breast Cancer after Primary
Chemotherapy
Yang SX, Loo WTY, Chow LWC, Yang XH, Zhan Y, Fan LJ, Zhang F, Li C, Wang QL,
Xiao HL, Wu JL, Bian XW, Jiang J
J of Tranlsational Medicine 2012 10 Suppl 1: S3
39.
LMTK3 is implicated in endocrine resistance via multiple signaling pathways
Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, Miki Y, Chow LWC,
Coombes RC, Sasano H, Shaw JA, Giamas G
Oncogene 2012 Aug 6
10
Chow L.W.C.
40.
Association of matrix metalloproteinase (MMP) -1, 3, 9, interleukin (IL)-2, 8 and
cyclooxygenase (COX)-2 gene polymorphisms with chronic periodontitis in a
Chinese population
Li GY, Yue Y, Tian Y, Li JL, Wang M, Liang H, Liao P X, Loo WTY, Cheung MNB,
Chow LWC
Cytokine 2012 Nov;60(2):552-60
41.
New therapies in HER2-positive breast cancer: a major step towards a cure of
the disease?
Awada A, Bozovic-Spasojevic I, Chow LWC
Cancer Treat Rev 2012; 38: 494-504
42.
Predictions of the pathological response to neoadjuvant chemotherapy in
patients with primary breast cancer using a data mining technique
Takada M, Sugimoto M, Ohno S, Kuroi K, Sato N, Bando H, Masuda N, Iwata H,
Kondo M, Sasano H, Chow LWC, Inamoto T, Naito Y, Tomita M, Toi M
Breast Cancer Res Treat 2012; 134: 661-670
43.
Aromatase inhibitor treatment of breast cancer cells increases the expression of
let-7f, a microRNA targeting CYP19A1
Shibahara Y, Miki Y, Onodera Y, Hata S, Chan MS M, Yiu CCP, Loo WTY,
Nakamura Y, Akahira JI, Ishida T, Abe K, Hirakawa H, Chow LWC, Suzuki T, Ouchi
N, Sasano H
J Pathol 2012; 227: 357-366
44.
Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis
Wang ZY, Loo WTY, Wang N, Chow LWC, Wang DM, Han F, Zheng X, Chen JP
Expert Opin Ther Targets 2012; 16 Suppl 1: S79-89
45.
Effects of estrogen depletion on angiogenesis in estrogen -receptor-positive
breast carcinoma--an immunohistochemical study of vasohibin -1 and CD31 with
correlation to pathobiological response of the patients in neoadjuvant
aromatase inhibitor therapy
Chan MS, Wang L, Chanplakorn N, Tamaki K, Ueno T, Toi M, Loo WTY, Chow
LWC, Suzuki T, Sasano H
Expert Opin Ther Targets 2012; 16 Suppl 1: S69-78
46.
Translational research to realize the full potential of novel agents --an
opportunity for vinflunine?
Yip AY, Ong EY, Chow LW
Expert Opin Drug Saf 2012; 11 Suppl 1: S5-8
47.
Increased 5α-reductase type 2 expression in human breast carcinoma following
aromatase inhibitor therapy: the correlation with decreased tumor cell
proliferation
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Wang L, Chan MS, Wing L, Yiu
CC, Chow LWC, Sasano H
Horm Cancer 2011; 2: 73-81
48.
Bone metabolism and quality-of-life of postmenopausal women with invasive
breast cancer receiving neoadjuvant hormonal therapy: sub -analyses from
celecoxib anti-aromatase neoadjuvant (CAAN) trial
Chow LWC, Yip AYS, Chu WP, Loo WT, Toi M
J Steroid Biochem Mol Biol 2011; 125(1-2): 112-119
11
Chow L.W.C.
49.
Spatholobus suberectus inhibits cancer cell growth by inducing apoptosis and
arresting cell cycle at G2/M checkpoint
Wang ZY, Wang DM, Loo TY, Cheng Y, Chen LL, Shen JG, Yang DP, Chow LWC,
Guan XY, Chen JP
J Ethnopharmacol 2011; 133: 751-1780
50.
Year in review in Asia - The major Asian trials published in 2011 on Breast
Cancer
Chow LWC, Yip AYS, Chu WP, Ong EYY
The Journal of Japan Society of Clinical Oncology 2011; 46: 1176-1181
51.
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy
in patients with early-stage breast cancer
Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow LWC, Yip AYS,
Glück S
Eur J Cancer 2011; 47: 2537-45
52.
Bone metabolism and quality-of-life of postmenopausal women with invasive
breast cancer receiving neoadjuvant hormonal therapy: Sub -analyses from
celecoxib anti-aromatase neoadjuvant (CAAN) trial
Chow LWC, Yip AYS, Chu WP, Loo WTY, Toi M
J Steroid Biochem Mol Biol 2011; 125 (1-2) : 112-9
53.
Epigenetic change in E-cadherin and COX-2 to predict chronic periodontitis
Loo WTY, Jin L, Cheung MNB, Wang M, Chow LWC
J Transl Med 2010; 8: 110
54.
Down-regulation of heat-shock protein 70 (HSP-70) correlated with
responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer
patients
Yiu CC, Chanplakorn N, Chan MS, Loo WT, Chow LW C, Toi M, Sasano H
Anticancer Res 2010; 30: 3465-3472
55.
The Breast Cancer Working Group presentation was divided into three sections:
the epidemiology, pathology and treatment of breast cancer
Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H, Park BW, Chow LW, Laudico
AV, Yip CH, Ueno E, Ishiguro H, Bando H
Jpn J Clin Oncol 2010; 40 Suppl 1: i13-18
56.
Rhodiola algida improves chemotherapy -induced oral mucositis in breast cancer
patients
Loo WTY, Jin LJ, Chow LWC, Cheung MNB, Wang M
Expert Opin Investig Drugs 2010; 19 Suppl 1: S91-S100
57.
Changes in protein expression after neoadjuvant use of aromatase inhibitors in
primary breast cancer: a proteomic approach to search for potential biomarkers
to predict response or resistance
Yiu CCP, Sasano H, Ono K, Chow LWC
Expert Opin Investig Drugs 2010; 19 Suppl 1: S79-S89
58.
Combat against cancer with science and medicine
Chow LWC, Toi M
Expert Opin Investig Drugs 2010; 19 Suppl 1: S3-S4
12
Chow L.W.C.
59.
Gene expression profiles as an additional tool to conventional predictive factors
to assist in management of early endocrine responsive breast cancer
Chow LWC
Expert Opin Investig Drugs 2010; 19 Suppl 1: S13-S17
60.
Combination of radiological and biochemical methods to assess bone mineral
density of mandible in fully edentulous patients after chemotherapy: a 5-year
prospective study
Loo WTY, Jin LJ, Cheung MNB, Chow LWC, Wang M
Expert Opin Investig Drugs 2010; 19 Suppl 1: S109-S115
61.
Expression of CD44V6 in parotid pleomorphic adenoma and carcinoma ex
pleomorphic adenoma
Yang S, Wang HP, Wang XY, Guo LJ, Tang XF, Gao QH, Xuan M, Loo WTY, Chow
LWC
Expert Opin Investig Drugs 2010; 19 Suppl 1: S101-S108
62.
Survival benefits from lapatinib therapy in women with HER2 -overexpressing
breast cancer: a systematic review
Yip AYS, Tse LA, Ong EYY, Chow LWC
Anticancer Drugs 2010; 21: 487-493
63.
Neratinib (HKI-272) 聯合紫杉醇治 ErbB2+ 中國轉移性乳腺癌患者的安全性及有
效性
江澤飛, 徐兵河, 楊俊蘭, Epstein R, Coughlin CM, Freyman A, Zhao Y, 孫強, 李維
廉, Kwong A, 周永昌
Linchuang Zhongliuxue Zazhi 2009; 60-61
64.
乳腺癌新輔助化療
Yip AYS, Ong EYY, Yiu CCP, Chow LWC
th
The 12 Annual Meeting of Chinese Society of Clinical Oncology (CSCO)
Educational Book. Chinese Peking Union Medical College Press 2009; pp525-529
65.
Breast cancer management: the way forward
Yip AYS, Chow LWC
Hong Kong Med J 2009; 15: 244-245
66.
Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase
in human breast carcinoma cells and tissues
Loo WTY, Chow LWC, Suzuki T, Ono K, Ishida T, Hirakawa H, Ohuchi N, Sasano H
Anticancer Res 2009; 29: 2525-2530
67.
Presence of extensive intraductal component in patients undergoing breast
conservative surgery predicts presence of residual disease in subsequent
completion mastectomy
Yiu CCP, Loo WTY, Lam CK, Chow LWC
Chin Med J (Engl) 2009; 122: 900-905
68.
Increased expression of annexin I is associated with drug -resistance in
nasopharyngeal carcinoma and other solid tumors
Chow BH, Chua DT, Sham JS, Zhang MY, Chow LW C, Bi J, Ma NF, Xie D, Loo WT,
Fung JM, Fu L, Guan XY
Proteomics Clin Appl 2009; 3: 654-662
69.
Latest world development in breast cancer treatment [Article in Chinese]
Yip AYS, Chow LWC
Chinese Journal of Breast Disease (Electronic Edition) 2009; 3:215-222
13
Chow L.W.C.
70.
Novel therapeutic strategy for breast cancer: mammalian target of rapamycin
inhibition
Yip AYS, Ong EYY, Chow LWC
Expert Opin Drug Discov 2009; 4:457-466
71.
Current treatment of locally advanced and metastatic breast cancer in the Asia –
Pacific region: Challenges and limitations
Chow LWC, Im YH
Asia Pac J Clin Oncol 2009; 4:S14-S23
72.
Breast-conserving surgery in Hong Kong Chinese women
Suen D, Chow LWC, Kwong A
World J Surg 2008; 32: 2549-2553
73.
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast
cancer
Chow LWC, Yip AYS, Loo WTY, Lam CK, Toi M
J Steroid Biochem Mol Biol 2008; 111: 13-17
74.
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally
advanced or metastatic breast cancer
Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow
LWC, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW.
J Clin Oncol 2008; 26: 2999-3005
75.
Evaluation of neoadjuvant inhibition of aromatase activity and signal
transduction in breast cancer
Chow LWC, Yip AYS, Loo WTY, Toi M
Cancer Lett 2008; 262: 232-238
76.
Vinflunine: Clinical perspectives of an emerging anticancer agent
Yip AYS, Ong EYY, Chow LWC
Expert Opin Investig Drugs 2008; 17: 583-591
77.
Factors predicting seroma formation after mastectomy for Chinese breast
cancer patients
Loo WTY, Chow LWC
Indian J Cancer 2007; 44: 99-103
78.
PTEN and VEGF: possible predictors for sentinel lymph node mi cro-metastasis in
breast cancer
Zhu L, Loo WT, Chow LWC
Biomed Pharmacother 2007; 61: 558-561
79.
Fructus Schisandrae (Wuweizi) containing compound in modulating human
lymphatic system – a Phase I minimization clinical trial
Yip AYS, Loo WTY, Chow LWC
Biomed Pharmacother 2007; 61: 588-590
80.
Neoadjuvant chemotherapy for breast cancer determined by chemosensitivity
assay achieves better tumor response
Lau GI, Loo WT, Chow LWC
Biomed Pharmacother 2007; 61: 562-565
14
Chow L.W.C.
81.
Effects of Shugansanjie Tang on matrix metalloproteinases 1, 3 and 9 and
telomerase reverse transcriptase expression in human breast cells in vitro
Loo WTY Chen JP, Chow LWC, Chou JW
Biomed Pharmacother 2007; 61: 601-605
82.
Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma
tissues and cell lines in vitro
Loo WTY, Sasano H, Chow LWC
Biomed Pharmacother 2007; 61: 553-557
83.
Fructus schisandrae (Wuweizi) containing compound inhibits secretion of HBsAg
and HBeAg in hepatocellular carcinoma cell line.
Loo WTY, Cheung MNB, Chow LWC
Biomed Pharmacother 2007; 61: 606-610
84.
Effects of capecitabine and vinorelbine on cell proliferation, metabolism and
COX2 and p16 expression in breast cancer cell lines and solid tumour tissues.
Loo WTY, Sasano H, Chow LWC
Biomed Pharmacother 2007; 61: 596-600
85.
Pro-inflammatory cytokine, matrix metalloproteinases and TIMP-1 are involved
in wound healing after mastectomy in invasive breast cancer patients.
Loo WTY, Sasano H, Chow LWC
Biomed Pharmacother 2007; 61: 548-552
86.
Chrysomya bezziana: a rare infestation of the breast
Kwong A, Yiu WK, Chow LWC, Wong S
Breast J 2007; 13: 297-301
87.
A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients
with pretreated metastatic breast cancer
Chow LWC, Yip AYS, Lang BHH
Am J Clin Oncol 2007; 30: 133-138
88.
A randomized controlled trial of psychosocial interventions using the
psychophysiological framework for Chinese breast cancer patients
Chan CL, Ho RT, Lee PW, Cheng JY, Leung PP, Foo W, Chow LW C, Sham JS,
Spiegel D
J Psychosoc Oncol 2006; 24: 3-26
89.
Breast cancer in limited-resource countries: an overview of the Breast Health
Global Initiative 2005 guidelines
Anderson BO, Shyyan R, Eniu A, Smith RA, Yip CH, Bese NS, Chow LW C, Masood
S, Ramsey SD, Carlson RW
Breast J 2006; 12 Suppl 1:S3-S15
90.
A new predictive and prognostic marker (ATP bioluminescence and positron
emission tomography) in vivo and in vitro for delivering adjuvant treatment
plan to invasive breast tumor patient
Loo WTY, Tong JM, Cheung MN, Chow LWC
Biomed Pharmacother 2006; 60: 285-288
91.
Prognostic contribution of the HER-2 oncogene overexpression to the
Nottingham Prognostic Index in breast cancer
Suen D, Chow LWC
Biomed Pharmacother 2006; 60: 293-297
15
Chow L.W.C.
92.
Increase in circulating VEGF levels during COX-2 inhibitor treatment in breast
cancer patients
Ueno T, Chow LWC, Toi M
Biomed Pharmacother 2006; 60: 277-279
93.
Clinical experience with docetaxel for Chinese breast cancer patients:
hematological toxicity profiles
Yip AYS, Chow LWC
Breast Cancer 2006; 13: 192-196
94.
Possible predictive markers related to micro-metastasis in breast cancer
patients
Zhu L, Loo WTY, Cheng CW, Chow LWC
Oncol Rep 2006; 15:1217-1223
95.
Cyclooxygenase-2 and Angiogenesis in Oncology (Editorial)
Chow LWC, Toi M
Biomed Pharmacother 2005; 59 Suppl 2: S263
96.
The efficacy of Paclitaxel on solid tumor analysed by ATP bioluminescence assay
and VEGF expression: A translational research study
Loo WTY, Fong JHM, Cheung MNB, Chow LWC
Biomed and Pharmacother 2005; 59 Suppl 2: S337-S339
97.
The value of bone marrow aspirates culture for detection of bone marrow
micrometastasis in breast cancer
Loo WTY, Fong JHM, Zhu L, Cheung MNB, Chow LWC
Biomed and Pharmacother 2005; 59 Suppl 2: S384-S386
98.
Study of COX-2, Ki67 and p53 are used to predict the chances of successful
chemotherapy treatment in breast cancer patients
Chow LWC, Loo WTY, Wai CCY, Lui ELH, Zhu L, Toi M
Biomed and Pharmacother 2005; 59 Suppl 2: S298-S301
99.
DNA Hypermethylation of TIMP3 gene in invasive breast carcinoma affect the
outcome of the treatment
Lui ELH, Loo WTY, Zhu L, Cheung MNB, Chow LWC
Biomed and Pharmacother 2005; 59 Suppl 2: S363-S365
100.
Current Directions for COX-2 Inhibition in Breast Cancer
Chow LWC, Toi M
Biomed and Pharmacother 2005; 59 Suppl 2: S281-S284
101.
Aberrant methylation of cyclooxygenase-2 in breast cancer patients
Chow LWC, Zhu L, Loo TY, Lui ELH
Biomed and Pharmacother 2005; 59 Suppl 2: S264-S267
102.
Circulating tumor cells in patients with breast cancer: predictor of micrometastasis in bone marrow but not in sentinel lymph nodes
Zhu L, Loo TYW, Chow LWC
Biomed and Pharmacother 2005; 59 Suppl 2: S355-S358
103.
Serum lipid profiles in patients receiving endocrine treatment for breast cancer
- the results from the Celecoxib Anti-Aromatase Neuoadjuvant (CAAN)Trial
Chow LWC, Cheng CWN, Wong JLN, Toi M
Biomed and Pharmacother 2005; 59 Suppl 2: S302-S305
16
Chow L.W.C.
104.
Trastuzumab: updates and future issues
Toi M, Horiguchi K, Bando H, Saji S, Chow LW C
Cancer Chemother Pharmacol 2005; 56 Suppl 1: S94-S99
105.
The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13
amplification and DNA methylation in breast cancer
Cheng CK, Chow LWC, Loo WTY, Chan TK, Chan V
Cancer Res 2005; 65: 8646-8654
106.
Phase II study on an “all oral” regimen of capecitabine, idarubicin and
cyclophosphamide of metastatic breast cancer: safety, efficacy and quality of
life
Tong DKH, Cheng CW, Chan SC, Wong LNJ, Chow LWC
Oncology 2005; 68: 520-525
107.
Association between body mass index and the risk of formation of breast cancer
in Chinese women
Chow LWC, Lui KL, Chan JC, Chan TC, Ho PK, Lee WY, Leung LH, Sy WM, Yeung
CC, Yung AK
Asian J Surg 2005; 28: 179-184
108.
The Chinese Medical Interview Satisfaction Scale -revised
development and validation
Lam WW, Fielding R, Chow LW, Chan M, Leung GM, Ho EY.
Qual Life Res 2005; 14:1187-1192
109.
Translational Research in Breast Cancer
Toi M, Takebayashi Y, Chow LWC
Breast Cancer 2005; 12: 86-90
110.
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in
cancer biology and treatment.
Toi M, Rahman MA, Bando H, Chow LWC
Lancet Oncol 2005; 6:158-166
111.
Gambling with your life: The process of breast cancer treatment decision
making in Chinese women
Lam WW, Fielding R, Chan M, Chow L, Or A
Psychooncology 2005; 14: 1-15
112.
Arimidex inhibition on proliferation of human breast solid tumors measured by
ATP bioluminescence
Tse EYT, Chow LWC, Loo WTY, Cheng CW
Life Sci 2004; 76: 827-834
113.
Production of matrix metalloproteinase in specific subpopulations of human patient breast cancer invading in 3-dimensional culture system
Loo TYW, Chow LWC, Cheung MB
Life Sci 2004; 76 :743-752
114.
Novel insights in clinical trials with preoperative systemic therapy for primary
breast cancer
Toi M, Bando H, Chow LWC
Biomed Pharmacother 2004; 58: 531-535
115.
The inhibitory effects of a herbal formula comprising ginseng and carthamus
tinctorius on breast cancer
Loo WTY, Chow LWC, Sham JST
Life Sci 2004; 76: 191-200
17
(C-MISS-R):
Chow L.W.C.
116.
Sentinel lymph node biopsy – here to stay (Editorial)
Chow LWC
Asian J Surg 2004; 27: 255
117.
Sentinel lymph node biopsy or detection of micrometastasis in bone marrow:
Which might be an alternative to axillary local lymph node dissection in breast
cancer patients?
Zhu L, Lam CK, Chow LWC
Asian J Surg 2004; 27: 279-283
118.
Radix bupleuri containing compound (KY88 liver -livo) induces apoptosis and
production of interleukin-4 and tumor necrosis factor-α in liver cancer cells in
vitro
Chow LWC, Loo WTY, Sham JST, Cheung MNB
Am J Chin Med 2004; 32: 185-193
119.
Her2/neu expression predicts the response to antiaAromatase neoadjuvant
therapy in advanced breast cancer: subgroup analysis from CAAN Trial
Zhu L, Chow LWC, Loo WTY, Guan XY, Toi M
Clin Cancer Res 2004; 10: 4639-4644
120.
Sentinel lymph node technique for breast cancer: Radiation safety issues for
radioguided surgery
Law M, Chow LWC, Lam CK, Kwong A, Yiu CCP
Semin Oncol 2004; 31:298-303
121.
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast
cancer: preliminary report
Chow LWC, Wong LNJ, Toi M
J Steroid Biochem Mol Biol 2003; 86:443-447
122.
Patient effective dose of sentinel lymph node lymphoscintigraphy in breast
cancer: a study using female humanoid phantom and thermoluminescent
dosimeters
Law M, Cheng KC, Wu PM, Ho WY, Chow LWC
Br J Radiol 2003; 76: 818-823
123.
Pattern of alternative medicine usage among the Chinese breast cancer
patients: implication for service integration
Abdullah ASM, Lau Y, Chow LWC
Am J Chin Med 2003; 31: 649-658
124.
Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer
patients: clinical implications
Hu XC, Wong I, Chow LWC
Oncol Rep 2003; 10: 1811-1815
125.
Participation and satisfaction with surgical treatment decision -making in breast
cancer among Chinese women
Lam W, Fielding R, Chan M, Chow L, Ho E
Breast Cancer Res Treat 2003; 80: 171-180
126.
Prospective pilot study of the preoperative use of celecoxib and FEC for locally
advanced breast cancer
Chow LWC, Toi M
Breast 2003; 12 Suppl 1:S40
18
Chow L.W.C.
127.
The study of cytokine dynamics at the operation site after mastectomy
Chow LWC, Loo WTY, Yuen KY, Cheng C
Wound Repair Regen 2003; 11: 326-330
128.
The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on
apoptotic marker (CPP-32), pro-apoptotic protein (p21WAF-1) and antiapoptotic protein (bcl-2) in breast cancer cells
Chow LWC, Loo TYW
Breast Cancer Res Treat 2003; 80: 239-244
129.
A rat cell line derived from DMBA-induced mammary carcinoma
Chow LWC, Cheung MNB, Loo WTY, Guan XY
Life Sci 2003; 73: 27-40
130.
Polysaccharide peptide mediates apoptosis by up -regulating p21 gene and
down-regulating cyclin D1 gene
Chow LWC, Lo CS, Loo WT, Hu XC, Sham JST
Am J Chin Med 2003; 31: 1-9
131.
Breast sentinel lymph node biopsy using radioisotope injection: is one -day
better than two-day protocol?
Chok SH, Chow LWC, Wong KH, Cheng KC, Ho WY
Am Surg 2003; 69: 358-361
132.
Surgery-related shedding of breast cancer cells as determined by RT -PCR assay
Hu XC, Loo TY, Chow LWC
J Surg Oncol 2003; 82: 228-232
133.
Immunomagnetic tumor cell enrichment is promising in detecting circulating
breast cancer cells
Hu XC, Wang Y, Shi DR, Loo TY, Chow LWC
Oncology 2003; 64: 160-165
134.
Cytokine production by human lymphocytes stimulated by a herbal compound
containing Bupleurum (KY88 LIVER LIVO)
Chow LWC, Loo TYW, Sham JST
Acta Pharmacol Sinica 2003; 24: 140-144
135.
Application of image-guided biopsy for impalpable breast lesions in Chinese
women
Tsang FHF, Lo JJ, Wong JLN, Lee FCW, Chow LWC
ANZ J Surg 2003; 73: 23-25
136.
Comparison of TPS with CEA and CA 15.3 in follow -up of Chinese breast cancer
patients
Hu XC, Day W, Jones B, Loo TY, Chow LWC
Anticancer Res 2002; 22: 1865-1868
137.
E-cadherin promoter methylation can regulate its expression in invasive ductal
breast cancer tissue in Chinese woman
Hu XC, Loo WTY, Chow LWC
Life Sci 2002; 71: 1397-1404
138.
Early introduction of clinical skills teaching in a medical curriculum —factors
affecting students' learning
Lam TP, Irwin M, Chow LWC, Chan P
Med Educ 2002; 36: 233-240
19
Chow L.W.C.
139.
Effects of a herbal compound containing bupleurum on human lymphocytes
Chow LWC, Loo WTY, Sham JST
Hong Kong Med J 2001; 7: 408-413
140.
Clinical value of serum tumor markers in breast cancer patients
Hu XC, Loo WTY, Chow LWC
Chin Med J 2001; 114: 6
141.
Sentinel lymph node biopsy for breast cancer
Ng KKC, Chow LWC
Ann Coll Surg HK 2001; 5: 116-120
142.
Neoadjuvant chemotherapy for Chinese women with locally advanced breast
cancer
Chow LWC, Day W, Ng KCK
Am Surg 2001; 67: 412-416
143.
Detection of circulating breast cancer cells with multiple -marker RT-PCR assay
Hu XC, Chow LWC
Anticancer Res 2001; 21: 421-424
144.
The use of focus group interviews in Asian medical education evaluative
research
Lam TP, Irwin M, Chow LWC, Chan P
Med Educ 2001; 35: 510-513
145.
The impact of postoperative nausea and vomiting on the practice of day surgery
for Chinese women with breast diseases
Choi HK, Chow LWC, Goh LC, Tsui SL, Lee F
Ambul Surg 2001; 9: 29-32
146.
Clarithromycin attenuates mastectomy-induced acute inflammatory response
Chow LWC, Yuen KY, Woo PCY, Wei WI
Clin Diagn Lab Immunol 2000; 7: 925-931
147.
Fine needle aspiration may shed breast cells into peripheral blood as
determined by RT-PCR
Hu XC, Chow LWC
Oncology 2000; 59: 217-222
148.
Hormonal receptor determination of 1,052 Chinese breast cancers
Chow LWC, Ho P
J Surg Oncol 2000; 75: 172-175
149.
Practice of breast self-examination among high risk Chinese women in Hong
Kong
Ng KKC, Fung SY, Chow LWC
Chin Med J 2000; 113: 1110-1113
150.
Detection of circulating breast cancer cells by reverse transcriptase polymerase
chain reaction (RT-PCR)
Hu XC, Chow LWC
Eur J Surg Oncol 2000; 26: 530-535
151.
MR appearance of metastatic melanotic melanoma in the breast
Ho LWC, Wong KP, Chan JH, Chow LWC, Leung EYF, Leong L
Clin Radiol 2000; 55: 572-573
20
Chow L.W.C.
152.
Comparison of tamoxifen with danazol in the management of idiopathic
gynecomastia
Ting ACW, Chow LWC, Leung YF
Am Surg 2000; 66: 38-40
153.
Acute myeloid leukemia relapsing as gynecomastia
Au WY, Ma ESK, Kwong YL, Lie AKW, Shek WH, Chow LWC, Liang R
Leuk Lymphoma 1999; 36: 191-194
154.
Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian
cancer
Khoo US, Ozcelik H, Cheung ANY, Chow LWC, Ngan HYS, Au GKH, Man EPS, Chan
V, Ng WF, Poon CSP, Leung YF, Loong F, Ip P, Chan GSW, Andrulis IL, Ho FCS
Oncogene 1999; 18: 4643-4646
155.
Clarithromycin attenuates the inflammatory response induced by surgical
trauma in a guinea pig model
Woo PCY, Chow LWC, Ma ESK, Yuen KY
Pharmacol Res 1999; 39: 49-54
156.
Bleeding peptic ulcer: an evolving role for surgical intervention
Branicki FJ, Ting ACW, Gertsch P, Tuen HH, Chu KM, Chow LWC, Wong J
J Gastroenterol Hepatol 1998; 13 Suppl: S227-S231
157.
Comparison of antiemetic efficacy of granisetron and ondansetron in Chinese
patients receiving chemotherapy for breast cancer: a randomised crossover
study
Poon RTP, Chow LWC
Br J Cancer 1998; 77: 1683-1685
158.
Bleeding peptic ulcer in the very elderly: risk factors for re-bleeding and
mortality
Chow LWC, Gertsch P, Poon RTP, Branicki FJ
Br J Surg 1998; 85: 121-124
159.
Lymphoma of the breast in Hong Kong Chinese
Au WY, Chan ACL, Chow LWC, Liang R
Haem Oncol 1997; 15: 33-38
160.
p53 expression in recurrent nodal metastases from nasopharyngeal carcinoma
Chow LWC, Khoo US, Yuen APW, Wei WI
Eur J Surg Oncol 1997; 23: 415-418
161.
Wide margin excision and brachytherapy for post -radiation breast cancer
recurrence
Chow LWC, Cheng ACK, Lam LK, Ho CM, Au GKH
J Surg Oncol 1997; 65: 55-56
162.
Breast conservative therapy for invasive breast cancer in Hong Kong: factors
affecting recurrence and survival in Chinese women
Chow LWC, Au GKH, Poon RTP
Aust NZ J Surg 1997; 67: 94-97
163.
Immunohistochemical analysis of antimeatstatic gene NM23 in human breast
carcinoma
Khoo US, Loong F, Chow LWC, Cheung KL, Ng WF, Cheung ANY
Pathol Int 1997; 47: A7
21
Chow L.W.C.
164.
Bleeding peptic ulcer in Hong Kong: stratification of risk factors in 1441 patients
Chow LWC, Ting ACW, Gertsch P, Branicki FJ
Asian J Surg 1997; 20: 279-282
165.
Current status of breast cancer in Hong Kong
Chow LWC, Ting ACW, Cheung KL, Au GKH, Alargaratnam TT
Chin Med J 1997; 110: 474-478
166.
Thoracoscopic vagotomy for the treatment of recurrent peptic ulcer after
surgery
Poon RTP, Chow LWC, Lim BH, Gertsch P
Aust NZ J Surg 1997; 67: 177-180
167.
Laparoscopic Taylor’s procedure in Chinese patients
Gertsch P, Chow LWC, Lim BH
Gastrointest Endosc 1996; 43: 243-247
168.
Long term survival time after gastrectomy for advanced bleeding or perforated
gastric carcinoma
Gertsch P, Chow LWC, Yuen ST, Chau KY, Lauder IJ
Eur J Surg 1996; 162: 723-727
169.
Update article – conservative breast surgery for breast cancer
Poon RTP, Chow LWC, Au GKH
Hong Kong Practitioner 1996; 18: 68-72
170.
Intrapancreatic avulsion of the common bile duct after blunt abdominal trauma
Chow LWC, Gertsch P, Cheung KL, Leung SYL
Eur J Surg 1996; 162: 519-521
171.
Atrophy of hand muscles and gastric cancer – coincidence or a paraneoplastic
manifestation
Chow LWC
South Med J 1995; 88: 961-963
172.
Gastric cancer with synchronous liver metastasis: palliative gastrectomy or not?
Chow LWC, Lim BH, Leung SYL, Branicki FJ, Gertsch P
Aust NZ J Surg 1995; 65: 719-723
173.
Pyogenic hepatic abscess and carcinoma of colon
Chow LWC, Lo CY, Ng WK, Gertsch P
Illustrated Case Reports in Gastroenterol 1995; 2: 5-10
174.
A pregnant woman with a rapidly growing breast lump
Khoo US, Chow LWC, Ho LWC, Tam R, Alagaratnam TT, Cheung ANY
Hong Kong Med J 1995; 1: 253-257
175.
Free perforation of gastric carcinoma: results of surgical treatment
Gertsch P, Yip SKH, Chow LWC, Lauder IJ
Arch Surg 1995; 130: 177-181
176.
Efficacy of leucocyte count and neutrophil percentage in the clinical diagnosis
of acute appendicitis
Chow LWC, Loh TKS, Ong CL, Png DJC
Asian J Surg 1994; 17: 49-52
22
Chow L.W.C.
177.
Retroperitoneal perforation complicating through -the-scope pyloric dilatation
Chow LWC, Ong CL
Gastrointest Endosc 1994; 40: 122-123
178.
Fournier’s gangrene
Chow LWC, Ong CL, Png DJC, Loh TKS, Rajagopalan R
Br J Clin Pract 1993; 47: 277-278
179.
Gallbladder empyema – another good reason for early cholecystectomy
Chow WC, Ong CL, Png DJC, Rauff A
J R Coll Surg Edinb 1993; 38: 213-215
180.
Massive per rectal bleeding from an ulceration in a jejunal diverticulum
Chow LWC, Ong CL, Png DJC
J Clin Gastroenterol 1993; 17: 85-86
181.
Role of sequential leucocyte counts and c-reactive protein measurements in
acute appendicitis
Chow LWC, Loh TKS, Ong CL
Brit J Surg 1993; 80: 673
182.
Necrotizing fasciitis revisited
Chow LWC, Ong CL, Png DJC, Loh TKS, Rajagopalan R
Contemp Surg 1993; 42: 181-184
183.
Percutaneous fine needle aspiration cytology for solid pulmonary lesions
Chow WC, Yip WC, Cheng CS, Lam HS, Chan NK, Gwi E, Nandi PL
Asian J Surg 1993; 16: 67-70
184.
Technical modification to laparoscopic appendectomy
Goh P, Tekant Y, Kum CK, Chow L, Ngoi SS
Dis Colon and Rectum 1992; 35: 999-1000
185.
Intracranial meningioma with metastatic breast carcinoma
Chow WC, Ho KH, Fong CM
Ann Oncol 1992; 3: 409-410
186.
Mirrzi syndrome with cholecystocholedochal fistula: preoperative diagnosis and
management
Yip WC, Chow WC, Chan J, Lam KH
Surgery 1992; 111: 335-338
187.
Tension pneumoperitoneum after colonoscopic polypectomy
Yip WC, Chow WC, Chan J
Endoscopy 1991; 23: 241
188.
Plea for selective operative cholangiography
Yip WC, Ng WS, Chow WC, Choi TK, Lam KH
J R Coll Surg Edinb 1991; 36: 21-24
189.
Interpostion drafting for femoral venous injury
Nandi PL, Chow WC, Yip WC
Asian J Surg 1990; 13: 222-225
190.
Removal of intrahepatic stone
Ng SK, Yip WC, Chow WC, Choi TK
Gastrointest Endosc 1990; 36: 402-404
23
Chow L.W.C.
Book Chapter
1.
Chow LWC. Combination Anti-aromatase therapy. In “Anti-Aromatase therapy for
Breast Cancer - New Developments”. Sasano H and Toi M Eds. Ch5; pp227 -235
2.
周永昌, 鲁慶榮. 實用乳腺病學. In “国际乳腺癌临床研究现状及展望 Practice of
Breast Diseases”. 崔维奇, 雷秋模, 左文迷, 张凤春, 漆幼珊, 彭成华. Ch1; pp5-24
Patent
A mouse cell line derived from human malignant cystosarcoma phylloides
Prizes
1.
第七届全国乳腺癌重庆论坛, Chongqing, China, December 21-23, 2012
(中华医学会金显宅乳腺癌研究纪念奖 /
Kim Hyun-Jib Breast Cancer Research Memorial Award)
2.
Cyclooxygenase-2: Possible Predictor Related to Micro -metastasis in Breast
Cancer Patients
Zhu L, Chow LWC
1st Annual Scientific Conference, Organisation for Oncology and Translational
Research, October 2004, Hong Kong
(Young Investigator Award)
The Correlation of Tumor Markers CEA and CA15.3 with the extent of breast
cancer using 18-flouro-2-deoxy-D-glucose positron emission tomography
18
( FDG-PET)
Kwong AK, Cheng CW, Yeung D, Lam CK, Chow LWC
Annual Congress, Asian Surgical Association, Kota Kinabalu, December 2003
(1st prize award for poster)
3.
4.
The use of Nottingham Prognostic index and c -erb-B2 status as prognostic
indicators of Chinese breast can cer
Kwong A, Chow LWC
1st Roche Asia Oncology Forum, Shanghai, China, September 2002
(1st prize award)
Research Supervision Experience
1.
Supervision of Ph.D. Student
Dr XC Hu: Detection of micrometastasis of breast cancer by RT -PCR
2.
Supervision of M MedSci Student
Dr Chung Pui Yi, Rebecca: Breast care module
3.
Supervision of MPhil Student
Dr Zhu Li: Detection of bone micrometastasis from breast cancer
4.
Supervision of MMedSci Student
Mr Eric Lui: TBC
Examiners for Postgraduate Examinations
1.
Internal Examiner for Dr K.C. Ng, Ph D Candidate, The University of Hong Kong,
2004
Local and systemic effects of hepatic radiofrequency ablation in animal models
24
Chow L.W.C.
2.
Additional Examiner for Professor ST Fan, PhD Candidate, The University of
Hong Kong, 2003
Adult-to-adult live donor liver transplantation using right lobe graft
3.
Internal Examiner for Ms Leung Wai Ching Wa, Gina, PhD candidate, The
University of Hong Kong, 2002
The influence of flutamide, tamoxifen and dietary fat on hormone-induced
mammary carcinogenesis
4.
Internal Examiner for Ms Mable Wu, MMedSci candidate, The University of
Hong Kong, 2002
5.
Internal Examiner for Mr Xi Chun Hu, PhD candidate, The University of Hong
Kong, 2001
Study on the Use of Potential Prognostic Parameters in Breast Cancer Patients
International Research Collaboration
Project
Tumour invasion and histoculture drug response assay (HDRA)
Collaborator
Dr Robert M. Hoffman
President, AntiCancer Inc, San Diego and Professor, Department
of Surgery, University of California, San Diego
Project
Collaborator
Changes in angiogenesis markers after neoadjuvant treatment
of breast cancer
Dr Masakazu Toi
Director, Department of Surgery, Tokyo Metropolitan Komagome
Hospital, Tokyo, Japan
Research/Professional Grants Awarded
1.
Chemosensitivity Testing Service for Selection of Chemotherapy in Breast
Cancer Patients (Project no.: 204217)
2.
3.
Source:
SK Yee Medical Foundation Grant 2004
Amount:
HK$1,158,753.20
The effects of psychosocial intervention on the psychosocial and
neuroendocrine outcomes: a prospective 3-group randomised trial with
Chinese breast cancer patients (as co-investigator)
Source:
RGC Competitive Earmarked Research Grant Award 2003 -2004
Amount:
HK$282,100
Radioguided Surgery and Breast Cancer Management Course and Seminars
(Ref: 2002-2-27)
4.
Source:
Professional Services Development and Assistance Scheme 2003
Duration:
2002-2004
Amount:
HK$249,000
Status:
stat
Project completed
Source:
CRCG Research Grant
Duration:
September 2002 to April 2004
Amount:
HK$120,000
Status:
stat
Project completed
Methylation changes during longitudinal follow-up of breast cancer patients
25
Chow L.W.C.
5.
Collaborative Laboratory Research on KY88 Liver Livo
Source:
Innovation and Technology Fund; University -Industry
Collaboration Programme
Duration:
April 2000 to March 2002
Amount:
HK$ 670,000
Status:
stat
Publications
Project completed
i.
Chow LWC, Loo WTY, Sham JST. Effects of Bupleurum containing herbal compound on
human lymphocytes. Hong Kong Med J. 2001; 7: 408-413
ii. Chow LWC, Loo WTY, Sham JST, et al. Radix bupleuri containing compound (KY88 liverlivo) induces apoptosis and production of interleukin-4 and tumor necrosis factor-α in
liver cancer cells in vitro. Am J Chin Med. 2004; 32: 185-193
iii. Chow WCL, Loo TY, Sham STJ Cytokine production by human lymphocytes stimulated by
a herbal compound containing Bupleurum (KY88 LIVER LIVO). Acta Pharmacol Sinica
2003; 24: 140-144
Donations
A total of HK$2,500,000 was donated from personal/company accounts to the
Division of Breast Surgery for research purposes
Applied/Translational Research
Co-investigator of International Clinical Trials (as listed in Clinical Trials Centre of HKU)
Protocol
HERA: A randomised three-arm multi-centre comparison of 1 year and 2
years of Herceptin® versus no Herceptin® in women with HER2 -positive
primary breast cancer who have completed adjuvant chemotherapy
Protocol No.: BIG01-01/BO16348B, Sponsored by Roche
Remarks: Completed patient enrolment
Protocol
A multicenter phase III randomized trial comparing Docetaxel in
combination with Doxorubicin and Cyclophosphamide (TAC) versus
Doxorubicin and Cyclophosphamide followed by Docetaxel (AC T) as
adjuvant treatment of operable breast cancer HER2/neu negative patients
with positive axillary lymph nodes. BCIRG 005
Protocol No.: BCIRG 005, Sponsored by Adventis
Remarks: Completed patient enrolment
Protocol
Multicenter Phase III Randomized Trial Comparing Doxorubicin and
Cyclophosphamide followed by Docetaxel (ACT) with Doxorubicin and
Cyclophosphamide followed by Docetaxel and Trastuzumab (Herceptin®)
(ACTH) and with Docetaxel, Carboplatin and Trastuzumab (TCH) in the
Adjuvant Treatment of Node Positive and High Risk Node Negative Patients
with Operable Breast Cancer containing the HER2 Alteration
Protocol No.: BCIRG 006, Sponsored by Adventis
Remarks: Completed patient enrolment
Protocol
Amonafide: Individual phenotype-adjusted chemotherapy for women with
metastatic breast cancer who have progressed despite prior chemotherapy
Protocol No.: 0001A1-200-GL, Sponsored by Xanthus, CRO: Orion
Remarks: Completed patient enrolment
Protocol
An Open-Label, Randomized, Multicenter Study to Evaluate the Use of
Zoledronic Acid in the Prevention of Cancer Treatment -Related Bone Loss in
Postmenopausal Women with ER+ and/or PgR+Breast Cancer Receiving
Letrozole as Adjuvant Therapy
Protocol No.: CFEM345D2405, Sponsored by Novartis
26
Chow L.W.C.
Protocol
A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial
Comparing Two Schedules of GW572016 as First -Line Monotherapy in
Patients with Advanced or Metastatic Breast Cancer.
Protocol No.: EGF 20009, Sponsored by GSK
Remarks: Completed patient enrolment
Principal Investigator of International Clinical Trials
1.
Prospective Randomized Celebrex Anti -Aromatase Neoadjuvant (CAAN) trial on
Locally Advanced Breast Cancer
2.
Phase II Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy
in Patients with Invasive Breast Cancer
3.
Evaluation of the Neoadjuvant Inhibition of Armoatase Activity and Signal
Transduction in Breast Cancer: The Femara/Glivec Study
4.
Randomized Trial of Docetaxel (T) with or without Capecitabine (X) as
Neoadjuvant Chemotherapy in Female Patients with Operable Breast Cancer
Who were not Observed Disease Progression after 4 cycles of 5-Fluorouracil,
Epirubicin and Cyclophosphamide (FEC)
Editorial Board Membership
1.
Member, International Editorial Committee, The Journal of Breast Cancer
2.
Member, Editorial Board, Chinese Journal of Surgical Therapy
3.
Member, Editorial Board, BMJ (Chinese)
4.
Member, Editorial Board, Update in Breast Cancer Therapy
5.
Guest Editor, Breast Cancer Symposium
Asian Journal of Surgery
6.
Member of Editorial Board, The Chinese Journal of Surgical Oncology
February 2004 – present
7.
Corresponding Editor, Chinese Medical Journal (Beijing)
Chinese Medical Association, China, June 2000 to present
8.
Editor, Faculty Newsletter
Faculty of Medicine, University of Hong Kong, April 2000 to present
Guest Editor
Symposium on Sentinel Lymph Node Biopsy, October Issue, 2004, Asian
Journal of Surgery
Journal Reviewer
1.
Annals of Hong Kong College of Surgeons
2.
Hong Kong Medical Journal
3.
Asian Journal of Surgery
27
Chow L.W.C.
4.
Journal of Pharmacology and Experimental Therapeutics
5.
Clinical Cancer Research
6.
Journal of Clinical Chemistry
7.
International Immunopharmacology
8.
Journal Biologia, Bratislava
9.
Journal of Breast Cancer (External Peer Reviewer)
10.
Chinese Journal of Traditional and Western Medicine (Executive Chief
Editor)
11.
Cancer Epidemiology, Biomarkers & Prevention (External Reviewer)
12.
Journal of Cancer Research and Therapeutics (External Reviewer)
13.
Annals of Oncology (External Reviewer)
Invited / Plenary Lectures
1.
乳腺癌手术：实践与研究
2013 年西南医院乳腺外科学术年会, Chongqing, China, December 14, 2013
2.
乳腺癌的治疗
第 一 届 深 港 肿 瘤 防 治 论 坛 暨 深 圳 市 抗 癌 协 会 学 术 年 会 , Shenzhen, China,
December 7, 2013
3.
乳腺癌轉化研究之晚期乳腺癌復發、轉移治療方法
第五屆江西乳腺疾病高層論壇, Jiangxi, China, November 22-23, 2013
4.
Refining Clinical Approach to HER2 -Positive Early Breast Cancer
Roche Korea Breast Cancer Forum, Gwangju, Korea, October 26-27, 2013
5.
The role of mTOR inhibitors in the management of advanced breast cancer
Philippines Breast Cancer Society Meeting, Manila, Philippines, October 23 -24,
2013
6.
Understanding Intratumor Heterogeneity
第 十 六 届 全 国 临 床 肿 瘤 学 大 会 暨 2013 年 CSCO 学 术 年 会 , Xiamen, China,
September 25-29, 2013
7.
乳腺癌肿瘤异质性
第五届全国乳腺微创外科大会, Chongqing, China, September 13-16, 2013
8.
早期乳腺癌的分子诊断与治疗
中国乳腺病论坛, Beijing, China, September 13-15, 2013
9.
香港年轻乳腺癌治疗现状
中国年轻乳腺癌南北高峰论坛, Wuyishan, China, August 10-11, 2013
10.
复发转移乳腺癌的治疗进展
甲状腺、乳腺疾病诊治新视觉学习班, Shenzhen, China, August 2, 2013
11.
New Strategies for an Evolving Disease
Breast Cancer Tour, Beijing & Shanghai, June 22-23, 2013
28
Chow L.W.C.
12.
乳腺癌个体化治疗的发展及挑战
第二届海峡乳腺论坛暨第四届福建省乳腺论坛, Xiamen, China, June 15-16, 2013
13.
How could we select patients for IORT after B reast Conservation Surgery
IORT in Breast Cancer Symposium, Hong Kong, China, May 27, 2013
14.
The Feasibility of IORT for Asian Breast Cancer Patients with Median Size
Breasts (Indications of IORT in Asian Breast Cancer Patients)
New Frontier in Breast Cancer Surgery - Trans-Asia Symposium of IntraOperative Radiotherapy & Surgical Techniques, Taipei, Taiwan, May 25, 2013
15.
Achieving Best Outcome of Conserving Breast Surgery
New Frontier in Breast Cancer Surgery - Trans-Asia Symposium of IntraOperative Radiotherapy & Surgical Techniques, Taipei, Taiwan, May 25, 2013
16.
HER2 陽性乳腺癌治療新進展
Macau Oncology Association Exchange Symposium, Macau, China, May 18, 2013
17.
乳腺癌治疗新突破
第 5 届广东乳腺病研讨会, Guangzhou, China, May 17-18, 2013
18.
A multimodality approach to neoadjuvant therapy for breast cancer
The 9th Annual Conference of the Organisation for Oncology and Translational
Research (OOTR) in conjunction with The Asian Oncology Summit (AOS) 2013,
Bangkok, Thailand, March 22-24, 2013
19.
Racial differences in breast cancer treatment
The 9th Annual Conference of the Organisation for Oncology and Translational
Research (OOTR) in conjunction with The Asian Oncology Summit (AOS) 2013,
Bangkok, Thailand, March 22-24, 2013
20.
从临床获益向乳腺癌个体化治疗的转变
The 5th Harbin Breast Cancer Forum, Harbin, China, January 5, 2013
21.
乳腺癌手术治疗之最新进展
第七届全国乳腺癌重庆论坛, Chongqing, China, December 21-23, 2012
22.
崭新靶向药物治疗耐药性乳腺癌
第五届粤港澳肿瘤大会暨第九届全国肿瘤综合治疗新进班, Zhongshan, China,
October 13-14, 2012
23.
乳腺癌外科的微创理念与进展
第三屆中國腫瘤外科微創學術研討會, Yinchuna, China, September 28-30, 2012
24.
What is Adequate Margin in Chinese Small or Medium Size Breast
2012 Taipei International Breast Cancer Symposium (TIBCS), Taipei, Taiwan,
September 21-23, 2012
25.
具抗药性乳腺癌病人的组合性用药治疗方案及其疗效和监察的探讨
The 15th Annual Meeting of Chinese Society of Clinical Oncology (CSCO),
Beijing, China, September 19-23, 2012
26.
探讨具抗药性乳腺癌病人临床组合性药物治疗的新方案及疗效的监察
江西南昌国际论坛, Nanchang, China, September 7-9, 2012
27.
Basal Subtype Breast Cancer - Therapeutic Implication
10th Asian Breast Diseases Association (ABDA) Teaching Course and Workshop,
Hong Kong, June 22-24, 2012
28.
Personalized Medicine in Breast Cancer
10th International Conference of Asian Clinical Oncology Society (ACOS), Seoul,
Korea, June 13-15, 2012
29
Chow L.W.C.
29.
Prevention
of oncological diseases
th
The 8 Annual Conference of Organisation for Oncology and Translational
Research (OOTR), Kyoto, Japan, April 20 -21, 2012
30.
Research into new targeting agents
Asian Oncology Summit (AOS) 2012, Singapore, April 13-15, 2012
31.
Prospective strategies to treat drug resistant cancers
Asian Oncology Summit (AOS) 2012, Singapore, April 13 -15, 2012
32.
乳腺癌的术前治疗策略
Chang Gung Memorial Hospital Breast Cancer Conference 2011, Taipei, Taiwan,
December 17, 2011
33.
Private Health Care Sector as an Alternative Study Site Provider
Clinical Trial Magnifier Conference 2011, Taipei, Taiwan, November 18 -20, 2011
34.
Current Status and Clinical Development of BC Stream
APECHO-LEAD Summit, Seoul, Korea, October 28-29, 2011
35.
Year in review in Asia
49th Annual Meeting of the Japanese Society of Clinical Oncology (JSCO), Aichi,
Japan, October 27-29, 2011
36.
乳腺癌的术前治疗策略
恶性肿瘤诊治新进展专题讨论会, Shenzhen, China, October 2 - 5, 2011
37.
乳腺癌新辅助治疗与耐药机制的探索
第四届全国乳腺微创治疗研讨会, Chongqing, China, September 23 – 26, 2011
38.
个体化新辅助治疗和辅助手段的应用
The 14th Annual Meeting of Chinese Society of Clinical Oncology (CSCO),
Xiamen, China, September 14 – 18, 2011
39.
Breast Cancer Therapy
9th Asia Pacific Oncology Summit (APOS), Bangkok, Thailand, August 19 – 20,
2011
40.
Personalizing Neoadjuvant Therapy and Applications Toward Adjuvant
Approaches
Asian Pacific Oncology Conference (APOC), Nanjing, China, July 15 – 17, 2011
41.
内分泌药物治疗对绝经后乳腺癌病人骨质疏松的影响
中国抗癌协会乳腺癌诊治指南与规范（2011 版）全国巡讲（江西站）暨第三届
江西乳腺疾病高层论坛, Nanchang, China, July 2 – 3, 2011
42.
Optimal use and future perspective of neoadjuvant therapy in breast cancer
Kyoto Breast Cancer Consensus Conference (KBCCC), Kyoto, Japan, April 14 – 16,
2011
43.
Expectations with Expertise: Practical Management Forum
Asian Oncology Summit (AOS) 2011, Hong Kong, April 8 – 10, 2011
44.
Application of biomarkers to sentinel lymph node biopsy for the management
of breast cancer
Asian Oncology Summit (AOS) 2011, Hong Kong, April 8 – 10, 2011
45.
Hormone therapy for metastatic breast cancer
Asian Oncology Summit (AOS) 2011, Hong Kong, April 8 - 10 2011
46.
Breast Reconstruction after Breast Conservative Surgery with Autologous
Tissue
3rd International Oncoplastic Breast Surgery Symposium, Tokyo, Japan,
November 25 – 26, 2010
30
Chow L.W.C.
47.
初期乳癌的診斷方法
第二届粵港澳檢驗醫學學術大會檢驗新進展國際研討會, Macau, November 5 -7,
2010
48.
Inter-disciplinary Expert Panel Discussion II N.O.T.E.S. - Chairman
2nd World (20th Chinese) Endoscopy Doctors Conference & 2nd Macau-Hong
Kong Surgical Scientific Meeting, Macau, October 29 – November 1, 2010
49.
國際乳腺癌臨床研究現狀和展望
第六届全国乳腺癌重庆论坛, Chongqing, China, September 24 – 26, 2010
50.
转化性研究与个人化治疗
The 13th Annual Meeting of Chinese Society of Clinical Oncology (CSCO),
Beijing, China, September 16 – 19, 2010
51.
Update Adjuvant Chemotherapy Focus on Triple -Negative Breast Cancer
Taipei International Breast Cancer Symposium, Taiwan, September 3 – 5, 2010
52.
Global and Asian consensus in breast cancer managements – case presenter
9th International Conference of The Asian Clinical Oncology Society (ACOS),
Gifu, Japan, August 25 – 27, 2010
53.
Do we need to perform lymphadenectomy if sentinel node is positive?
UICC World Cancer Congress, Shenzhen, China , August 18 – 21, 2010
54.
Investigator Breast Cancer Trial Network in China and Asia
Clinical Trial Magnifier 2009 Conference (CTC), Hong Kong, November 13-15,
2009
55.
General Situation of Breast Cancer and Screening in Hong Kong and Macao
The Second Asia Pacific Health Symposium, Tainan, Taiwan, November 8, 2009
56.
乳腺癌 HER2 信号传导研究进展
The 12th Annual Meeting of Chinese Society of Clinical Oncology (CSCO),
Xiamen, China, October 2009
57.
乳腺癌新辅助化疗
th
The 12 Annual Meeting of Chinese Society of Clinical Oncology (CSCO),
Xiamen, China, October 2009
58.
Towards Anthracycline-free in Adjuvant Setting
th
Global Breast Cancer Conference 2009 with the 7 Biennial Meeting of the
Asian Breast Cancer Society (ABCS), Seoul, Korea, October 2009
59.
Introduction of Breast Cancer
Breast Cancer Nurse Workshop, St. Teresa Hospital, Hong Kong, September
2009
60.
Breast Cancer Treatment Developments by Clinical Trials in Asia
International Surgical Week 2009, Adelaide, Australia, September 2009
61.
Progress in Preoperative Therapy in Breast Cancer
nd
The 2 International Symposium on the Prevention of Breast Cancers, Taiwan,
August 2009
62.
乳癌近十年之治療進展
癌症治療講座, Hong Kong, July 2009
31
Chow L.W.C.
63.
Insights Into Evolving Breast Cancer Practice Patterns in China
Breast Cancer Congress, Maui, Hawaii, United States of America, July 2009
64.
Progress in Preoperative Therapy
Breast Cancer Congress, Maui, Hawaii, United States of America, July 2009
65.
亚洲乳腺癌筛查现状
早期诊断专题研討會, Shenzhen, China, July 2009
66.
Network Formation for Sharing of Clinical Data
2009 년 한국유방암학회 춘계학술대회, Jeju, Korea, June 2009
67.
Breast Cancer Screening – Biofield Diagnostic System
Manila, April 2009
68.
Sentinel Lymph Node Biopsy: Before or After Preoperative Chemotherapy
Asian Oncology Summit (AOS), Singapore, April 2009
69.
Surgeon’s Consideration of Image Guided Biopsy for Impalpable Breast Lesions
Taiwan, April 2009
70.
New Trials and Chemoprevention in Asia
th
5 Annual Scientific Conference of Organisation for Oncology and Translational
Research, Macau SAR, February 2009
71.
Multidisciplinary Management of Early Breast Cancer in China: Current
Challenges
th
5 Annual Scientific Conference of Organisation for Oncology and Translational
Research, Macau SAR, February 2009
72.
Bevacizumab: A Blend into Traditional Chemotherapy with Translational
Research
th
7 Roche Asia Oncology Forum 2008, Bangkok, November 2008
73.
香港乳腺癌篩查和早期診斷的經驗
早期乳腺癌研討會, Shenzhen, China, November 2008
74.
Case Presentation
th
The 6 Asia Pacific Oncology Summit, Xian, October 2008
75.
Make Right Decisions for Patients – The Progress on The Hormonal Therapy in
Breast Cancer
AstraZeneca satellite meeting, Shanghai, China, Oct ober 2008
76.
Satellite Symposium – Breast Cancer Surgery
th
15 World Congress on breast disease, Shanghai, October 2008
77.
Neoadjuvant Trials in Asia
th
15 World Congress on beast disease Shanghai, October 2008
78.
A New Era of Hormonal Therapy in Breast Cancer Treatment
IX International Aromatase Conference, Shanghai, Oct ober 2008
79.
國際乳腺癌治療新動態
2008 第五屆乳腺癌重慶論壇, Chongqing, China, October 2008
80.
Neoadjuvant Hormonal Therapy for Breast Cancer
2008 廣 州 乳 腺 癌 臨 床 診 治 論 壇 暨 第 二 屆 中 大 一 哈 佛 乳 腺 癌 學 術 研 討 會 ,
Guangzhou, September 2008
32
Chow L.W.C.
81.
賀爾蒙週期變化與乳腺癌的關係
Macau, September 2008
82.
Tailoring and expanding the role of erbB2 targeted agents in breast cancer
Annual meeting of the Taiwan Breast Cancer Society, Taipei, September 2008
83.
Future Potential of ErbB2 Targeted Therapy in Early BC
Chinese Society of Clinical Oncology Annual Meeting, Shanghai, Aug ust 2008
84.
Satellite Symposium
th
The 9 Annual conference of Korean Breast Cancer Society, South Korea, June
2008
85.
Overview of targeted therapy in breast cancer
國際乳腺癌臨床及病理診斷及治療標準化研討會, 中國銀川, 5 月 2008 年
86.
International clinical practice guidelines for breast cancer
國際乳腺癌臨床及病理診斷及治療標準化研討會, 中國銀川, 5 月 2008 年
87.
Current Treatment of Locally Advanced Breast Cancer in the Asia-Pacific
Region, Including Neoadjuvent Therapy – Challenges and Limitations
Scientific and Clinical Expert Panel Meeting, Singapore, March 2008
88.
Tyrosine Kinase Inhibitors in Breast Cancer – Current Experience and Future
Perspectives
st
Industry Satellite Symposium, 1 Asian Breast Cancer Congress, India, February
2008
89.
Breast Cancer Management in Hong Kong
21 世紀亞太乳房健康管理研討會, December 2007
90.
Lapatinib as A First-line Treatment in Patients with ErbB2 Positive Advanced
or Metastatic Breast Cancer and Biomarkers Analysis
Global Breast Cancer Conference, October 2007
91.
Neoadjuvant Hormonal Therapy for Breast Cancer
Global Breast Cancer Conference, October 2007
92.
Clinical Trial in Asian
th
6 Asian Breast Cancer Conference, September 2007
93.
乳腺癌手術治療新進展
澳門腫瘤醫學會第二屆學術年會, Macau, September 2007
94.
乳癌之外物及藥物治療
澳門中華醫學會持續醫學教育課程, Macau, September 2007
95.
Timing and Translational aspects in Trastuzumab therapy
th
6 Roche Asian Oncology Forum (RAOF), Malaysia, August 2007
96.
乳腺癌生物靶向治療
2007 中國普外科焦點問題學術論壇, China, August 2007
97.
Phase 3 Study of Temsirolimus with Letrozole or Letrozole Alone in
Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer
Sendai, Japan, February 2007
98.
Lapatinib Single Agent in First line Metastatic Breast Cancer
Asiapac Breast Cancer Experts Meeting, Singapore November 2006
33
Chow L.W.C.
99.
Future Directions : Clinical Research and New Medicine for Women ’s Cancer
Beijing Women’s Health Summit, Beijing, China, November 2006
100.
Creating New Strategies for Cancer Therapy and Prevention
nd
2 Annual Conference of the Organisation for Oncology and Translational
Research, Tokyo, Japan, November 2005
101.
Paradigm Shift in The Management of Breast Cancer
Special Lecture, Shanghai Cancer Hospital, Shanghai, China, October 2004
102.
Clinical Experience on COX-2 Inhibition in Breast Cancer
st
1 Annual Conference, Organisation for Oncology and Translational Research
Hong Kong, October 2004
103.
Keynote Lecture: Current Direction of COX -2 Inhibition in Breast Cancer
Second Asia Pacific Oncology Summit: Commitment to Advancing the Treatment
of Solid Tumors, Suzhou, China, October 2004
104.
New Paradigm in the Treatment of Breast Cancer
2004 National Congress on the Diagnosis and Management of Breast Cancer
The Breast Society of the Chinese Medical Association , Chongqing, China,
September 2004
105.
Neoadjuvant Therapy for Breast Cancer
Tohoku University Faculty of Medicine, Sendai, Japan, July 2004
106.
Neoadjuvant Therapy for Breast Cancer
Inaugural Stanford-Hong Kong Oncology Teleconference and Seminar – Update
in Breast Cancer Investigation and Treatment , Hong Kong, April 2004
107.
Neoadjuvant Hormonal Therapy
Key Advances in the Treatment of Breast Cancer, Hong Kong, February 2004
108.
Clinical Management of Women with BRCA1 or BRCA2
Asian Breast Cancer Conference, Taipei, February 2004
109.
To Screen or Not To Screen: The Evidences
th
10 Hong Kong International Cancer Congress, Hong Kong, November 2003
110.
Stereotatic Breast Biopsy with Vacuum Assisted Minimally Invasive Biopsy
Technology
First Mammotome Asia Pacific Summit Meeting, Shanghai, China November
2003
111.
Celecoxib Anti-aromatase Neoadjuvant (CAAN) Trial for Locally Advanced
Breast Cancer: Preliminary Report
First Asia Pacific Oncology Summit, Hanoi, China, October 2003
112.
Phase II Study on An “All-oral” Regimen of Capecitabine, Idarubicin and
Cyclophosphamide in Metastatic Breast Cancer; -Possibility and EfficacyThe 2nd Roche Asia Oncology Forum, Taipei, October 2003
113.
Introduction to Breast Mapping
Radioguided Breast Cancer Surgery Symposium, The Breast Cancer Society of
Taiwan, November 2002
34
Chow L.W.C.
114.
Celebrex Anti-aromatase Neoadjuvant Trial for Locally Advanced Breast
Cancer
VI International Aromatase Conference - Aromatase 2002: The new millennium,
Kyoto, October 2002
115.
All-oral Combination Therapy and Practical Patient Management with Xeloda
st
1 Roche Asia Oncology Symposium, Shanghai, China, September 2002
116.
Current Treatment of Breast Cancer
Making the Difference in the Management of Breast Cancer, Pharmacia
Symposium, Xian, China, June 2002
117.
Radioguided Surgery for Breast Cancer
Chinese Medical Association, Breast Cancer Group, Beijing, China, March 2002
118.
Sentinel Biopsy for Breast Cancer
Hong Kong Surgical Forum, Hong Kong, January 2002
119.
Sentinel Biopsy for Breast Cancer
Eight Joint Shanghai/Hong Kong Surgical Convention, Shanghai, January 2002
120.
Breast Cancer in Hong Kong
th
The 5
Symposium of the Shanghai Anti-Cancer Association, Yangzhou,
November 2001
121.
Locally Advanced Breast Cancer
th
The 13 Biennial Congress of the Asian Surgical Association, Singapore,
November 2001
122.
Sentinel Lymph Node Biopsy in Breast Cancer Management
th
8 Hong Kong International Cancer Congress, Hong Kong, September 2001
123.
Debate on Breast Cancer Screening
th
8 Hong Kong International Cancer Congress, Hong Kong, September 2001
124.
Sentinel Lymph Node Biopsy in BC Management – Theory and Practice
st
1 Meeting of the Chinese Breast Cancer Society, Chongqing, China, September
2001
125.
Management of Breast Cancer
Hong Kong Medical Association CME Program 2001, , Hong Kong, July 2001
126.
The Epidemiology of Breast Cancer in Hong Kong
rd
The 3 Biennial Meeting of the Asian Breast Cancer Society, Seoul, Korea, June
2001
127.
Epirubicin-Based Neoadjuvant and Adjuvant Treatment of Breast Cancer
th
5 International Conference of the Asian Clinical Oncology Society & the 6th
Taiwan Joint Cancer Conference, Taipei, April 2001
128.
Management of Impalpable Breast Cancer
nd
The 2
Cross-Strait & World Chinese General Surgical Congress, Chinese
Surgical Society, Wuhan, China, November 2000
129.
Management of Locally Advanced Breast Cancer in Hong Kong
Taipei International Breast Cancer Symposium, Taipei, October 2000
130.
Breast Cancer Screening – an Overview
Symposium on Molecular Medicine for the Practising Clinicians, Centre of
Endocrinology & Diabetes, University of Hong Kong, May 2000
35
Chow L.W.C.
131.
Local Experience in the Use of Xeloda in the Management of Metastatic Breast
Cancer
Scientific Symposium, Hong Kong Anticancer Society, April 2000
132.
Tamoxifen in Prevention of Breast Cancer
th
6 Hong Kong International Cancer Congress, November 1999
133.
Breast Conservation Surgery
th
6 Hong Kong International Cancer Congress, November 1999
134.
Mechanism of Actions of TCM: Laboratory Studies
th
6 Hong Kong International Cancer Congress, November 1999
135.
Tumour Markers in the Management of Breast Cancer
th
12 Biennial Congress, Asian Surgical Association and Royal Australasian
College of Surgeons, Brisbane, Australia, March 1999
136.
Critical Evaluation and Practical Application of Prognostic Factors
Advanced Workshop in Breast Cancer Management, European School of
Oncology and Kwong Wah Hospital, Hong Kong, November 1998
137.
The effect of Polysaccharide Peptide (PSP) in breast cancer
Symposium on Advances in Traditional Chinese Medicine, University of Hong
Kong, June 1998
138.
Application of Chemosensitivity Testing in Breast Cancer
th
th
14 Asian Pacific Cancer Congress and 4 Hong Kong International Cancer
Congress, Hong Kong, November 1997
139.
Management of Ductal Carcinoma In-Situ
th
th
14 Asian Pacific Cancer Congress and 4 Hong Kong International Cancer
Congress, Hong Kong, November 1997
140.
Prognostic Factors of Breast Cancer
th
110 Anniversary & Medical Congress, University of Hong Kong, Hong Kong,
October 1997
141.
Predictors of Response of Breast Cancer
th
11 Biennial Congress, Asian Surgical Association, Hong Kong, March 1997
142.
The Management of Recurrent Breast Cancer
th
11 Biennial Congress, Asian Surgical Association, Hong Kong, March 1997
143.
Surgical Treatment of Invasive Breast Cancer in Hon g Kong
Breast Cancer Symposium, 16th Annual Meeting, Chinese Medical Association,
Taiwan, June 1996
144.
Treatment of Breast Cancer in Hong Kong
Japanese Breast Cancer Society, Osaka, 1996
145.
Use of Prognostic Factors in Patient Management - Clinician’s Point of View
Workshop on Breast Diseases, Hong Kong Pathology Society, May 1995
146.
Extent and Limits of Surgery - Breast Cancer
Surgical Forum, The University of Hong Kong, July 1994
36